在风险评估与缓解策略计划中利用技术。
Leveraging Technology in Risk Evaluation and Mitigation Strategy Programs.
作者信息
Davis Sondra, Reynolds Katie, Ulrich Charles
机构信息
Medical City Arlington, Arlington, TX.
出版信息
HCA Healthc J Med. 2023 Apr 28;4(2):91-93. doi: 10.36518/2689-0216.1558. eCollection 2023.
Abstract
Description Medication safety is improved through REMS programs. Multidisciplinary teams and front-line staff are vital in setting up a REMS program and should be included in any discussions surrounding REMS programs. Certain components of the REMS requirements may be replaced with CDS screens. Utilizing technology can help advance patient safety and aid in regulatory compliance.
摘要
说明 通过风险评估与缓解策略（REMS）计划可提高用药安全性。多学科团队和一线工作人员对于建立REMS计划至关重要，应纳入围绕REMS计划的任何讨论中。REMS要求的某些组成部分可用临床决策支持（CDS）屏幕替代。利用技术有助于提高患者安全并有助于符合监管要求。
相似文献
1
Leveraging Technology in Risk Evaluation and Mitigation Strategy Programs.在风险评估与缓解策略计划中利用技术。
HCA Healthc J Med. 2023 Apr 28;4(2):91-93. doi: 10.36518/2689-0216.1558. eCollection 2023.
2
Pragmatic applications of implementation science frameworks to regulatory science: an assessment of FDA Risk Evaluation and Mitigation Strategies (REMS) (2014-2018).实施科学框架在监管科学中的务实应用：对 FDA 风险评估和缓解策略 (REMS) 的评估 (2014-2018 年)。
BMC Health Serv Res. 2021 Aug 6;21(1):779. doi: 10.1186/s12913-021-06808-3.
3
A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs.一种评估风险评估与缓解策略（REMS）项目影响的多模态方法。
Drug Saf. 2021 Jul;44(7):743-751. doi: 10.1007/s40264-021-01070-2. Epub 2021 Apr 27.
4
Adaptation for Regulatory Application: A Content Analysis of FDA Risk Evaluation and Mitigation Strategies Assessment Plans (2014-2018) Using RE-AIM.监管应用的适应性：使用RE-AIM对美国食品药品监督管理局风险评估和缓解策略评估计划（2014 - 2018年）进行的内容分析
Front Public Health. 2020 Feb 25;8:43. doi: 10.3389/fpubh.2020.00043. eCollection 2020.
5
Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use.患者和照护者对具有确保安全使用要素的风险评估和缓解策略计划的体验和看法。
JAMA Netw Open. 2022 Jan 4;5(1):e2144386. doi: 10.1001/jamanetworkopen.2021.44386.
6
APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.APhA 2011 REMS 白皮书：改善项目设计和实施的 REMS 利益相关者会议总结。
J Am Pharm Assoc (2003). 2011 May-Jun;51(3):340-58. doi: 10.1331/JAPhA.2011.11519.
7
Implementation and Use of Risk Evaluation and Mitigation Strategies Programs in Practice: A Scoping Review of the Literature.风险评估和缓解策略计划在实践中的实施和使用：文献综述的范围界定。
Appl Clin Inform. 2022 Oct;13(5):1151-1160. doi: 10.1055/s-0042-1758838. Epub 2022 Dec 8.
8
Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.风险评估和缓解策略：对患者、医疗保健提供者和卫生系统的影响。
Am J Health Syst Pharm. 2009 Dec 15;66(24 Suppl 7):S6-S12. doi: 10.2146/ajhp090461.
9
Risk evaluation and mitigation strategies: assessment of a medical center's policies and procedures.风险评估和缓解策略：评估医疗中心的政策和程序。
Am J Health Syst Pharm. 2012 May 15;69(10):885-9. doi: 10.2146/ajhp110356.
10
Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function.遵守风险评估与缓解策略（REMS）中关于每月进行肝功能检测的要求。
Drugs Context. 2015 Feb 10;4. doi: 10.7573/dic.212272. eCollection 2015.
本文引用的文献
1
What is the quality of drug safety information for patients: An analysis of REMS educational materials.患者用药安全信息的质量如何：风险评估和缓解策略（REMS）教育材料分析
Pharmacoepidemiol Drug Saf. 2018 Sep;27(9):969-978. doi: 10.1002/pds.4614. Epub 2018 Jul 13.
2
Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention.来那度胺和沙利度胺风险评估与缓解策略（REMS）的有效性：患者理解与知识留存
Drug Saf. 2017 Apr;40(4):333-341. doi: 10.1007/s40264-016-0501-2.
3
Impact of a Pharmacy-Cardiology Collaborative Practice on Dofetilide Safety Monitoring.药学-心脏病学协作实践对多非利特安全性监测的影响。
Ann Pharmacother. 2017 Jan;51(1):39-43. doi: 10.1177/1060028016669962. Epub 2016 Oct 1.
4
Risk evaluation and mitigation strategy programs in solid organ transplantation: the promises of information technology.实体器官移植中的风险评估和缓解策略计划：信息技术的承诺。
J Am Med Inform Assoc. 2014 Oct;21(e2):e358-62. doi: 10.1136/amiajnl-2013-002446. Epub 2014 Feb 26.
5
APhA 2011 REMS white paper: Summary of the REMS stakeholder meeting on improving program design and implementation.APhA 2011 REMS 白皮书：改善项目设计和实施的 REMS 利益相关者会议总结。
J Am Pharm Assoc (2003). 2011 May-Jun;51(3):340-58. doi: 10.1331/JAPhA.2011.11519.
Zotero 插件